On February 6, 2024 Triumvira Immunologics on Monday reported it began dosing patients in a Phase I/II trial or an autologous T-cell antigen coupler (TAC) therapy, TAC101-CLDN18.2, targeting claudin 18.2 (CLDN18.2)-positive solid tumors (Press release, Triumvira Immunologics, FEB 6, 2024, View Source [SID1234639946]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the same time, in an effort to optimize finite resources, the Austin, Texas-based company has paused clinical development of its HER2-targeted TAC agent, TAC 100-HER1 (formerly TAC01-HER2), and is focusing instead on the CLDN18.2 program, said Robert Williamson, Triumvira’s president and chief operating officer.